|
WO2021063914A1
|
|
4-quinolinone antibacterial compounds
|
|
WO2021063915A1
|
|
Antibacterial compounds
|
|
WO2021048342A1
|
|
Antibacterial compounds
|
|
WO2021023662A1
|
|
Pyrazolo[4,3-c]pyridine compounds for use in the treatment of hbv infection
|
|
WO2021018238A1
|
|
Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
|
|
WO2021018237A1
|
|
Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
|
|
WO2021018239A1
|
|
Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
|
|
WO2021001508A1
|
|
Methods of treating hiv in pediatric patients with rilpivirine
|
|
WO2020255055A1
|
|
Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
|
|
WO2020255063A1
|
|
Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
|
|
WO2020255062A1
|
|
Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
|
|
WO2020255013A1
|
|
Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
|
|
WO2020255015A1
|
|
Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
|
|
WO2020255023A1
|
|
Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
|
|
WO2020255019A1
|
|
Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative
|
|
WO2020255038A1
|
|
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
|
WO2020255022A1
|
|
Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
|
|
WO2020255018A1
|
|
Hepatitis b virus (hbv) vaccines and uses thereof
|
|
WO2020255011A1
|
|
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
WO2020255012A1
|
|
Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
|
